CN100388927C - 一种治疗中风病的药物及制备方法 - Google Patents
一种治疗中风病的药物及制备方法 Download PDFInfo
- Publication number
- CN100388927C CN100388927C CNB2005100019511A CN200510001951A CN100388927C CN 100388927 C CN100388927 C CN 100388927C CN B2005100019511 A CNB2005100019511 A CN B2005100019511A CN 200510001951 A CN200510001951 A CN 200510001951A CN 100388927 C CN100388927 C CN 100388927C
- Authority
- CN
- China
- Prior art keywords
- hirudo
- blood
- weight portion
- rhizoma chuanxiong
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 28
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 27
- 208000006011 Stroke Diseases 0.000 title claims abstract description 27
- 230000008569 process Effects 0.000 title claims description 23
- 229940079593 drug Drugs 0.000 title description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 42
- 239000002552 dosage form Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 81
- 241000237903 Hirudo Species 0.000 claims description 76
- 239000000843 powder Substances 0.000 claims description 72
- 239000000706 filtrate Substances 0.000 claims description 69
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 58
- 239000012141 concentrate Substances 0.000 claims description 45
- 230000006837 decompression Effects 0.000 claims description 44
- 210000000582 semen Anatomy 0.000 claims description 44
- 239000009636 Huang Qi Substances 0.000 claims description 37
- 238000003756 stirring Methods 0.000 claims description 26
- 238000001556 precipitation Methods 0.000 claims description 23
- 238000000108 ultra-filtration Methods 0.000 claims description 23
- 241001061264 Astragalus Species 0.000 claims description 22
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 22
- 235000006533 astragalus Nutrition 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 22
- 244000144992 flock Species 0.000 claims description 22
- 238000010992 reflux Methods 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 22
- 238000004108 freeze drying Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 3
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 2
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 3
- 241000545744 Hirudinea Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 240000006413 Prunus persica var. persica Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 70
- 239000008280 blood Substances 0.000 description 70
- 235000008504 concentrate Nutrition 0.000 description 43
- 239000000243 solution Substances 0.000 description 29
- 210000004556 brain Anatomy 0.000 description 25
- 230000017531 blood circulation Effects 0.000 description 24
- 230000007812 deficiency Effects 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 239000002244 precipitate Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 206010008118 cerebral infarction Diseases 0.000 description 13
- 201000006474 Brain Ischemia Diseases 0.000 description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 229920001353 Dextrin Polymers 0.000 description 7
- 239000004375 Dextrin Substances 0.000 description 7
- 206010019468 Hemiplegia Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 235000019425 dextrin Nutrition 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 210000001168 carotid artery common Anatomy 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000007908 dry granulation Methods 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 210000003446 pia mater Anatomy 0.000 description 6
- 210000002385 vertebral artery Anatomy 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010041956 Stasis syndrome Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 208000005634 blind loop syndrome Diseases 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229960000715 nimodipine Drugs 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008899 fufang danshen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- -1 tincture Substances 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000008923 Qingkailing Substances 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 239000009798 Shen-Fu Substances 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000010225 buchang naoxintong Substances 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000009019 naodesheng Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100019511A CN100388927C (zh) | 2005-01-13 | 2005-01-13 | 一种治疗中风病的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100019511A CN100388927C (zh) | 2005-01-13 | 2005-01-13 | 一种治疗中风病的药物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1803156A CN1803156A (zh) | 2006-07-19 |
CN100388927C true CN100388927C (zh) | 2008-05-21 |
Family
ID=36865389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100019511A Active CN100388927C (zh) | 2005-01-13 | 2005-01-13 | 一种治疗中风病的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100388927C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113813291B (zh) * | 2021-11-10 | 2023-05-26 | 鲁南制药集团股份有限公司 | 一种动物药材冻干粉的制备方法 |
CN116036172A (zh) * | 2022-12-26 | 2023-05-02 | 林绍振 | 治疗面瘫的膏药贴及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1119116A (zh) * | 1995-08-08 | 1996-03-27 | 王文惠 | 一种用于治疗心脑血管疾病的药物及其制备方法 |
CN1182604A (zh) * | 1996-11-20 | 1998-05-27 | 甘肃省中医院 | 中风膏 |
-
2005
- 2005-01-13 CN CNB2005100019511A patent/CN100388927C/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1119116A (zh) * | 1995-08-08 | 1996-03-27 | 王文惠 | 一种用于治疗心脑血管疾病的药物及其制备方法 |
CN1182604A (zh) * | 1996-11-20 | 1998-05-27 | 甘肃省中医院 | 中风膏 |
Non-Patent Citations (6)
Title |
---|
中医药治疗中风急性期的研究进展. 徐保宁.《天津中医》,第14卷第5期. 1997 |
中医药治疗中风急性期的研究进展. 徐保宁.《天津中医》,第14卷第5期. 1997 * |
复方黄芪合剂的制备与疗效观察. 胡同瑜,庞治功.《中药材》,第18卷第10期. 1995 |
复方黄芪合剂的制备与疗效观察. 胡同瑜,庞治功.《中药材》,第18卷第10期. 1995 * |
益气活血法防治缺血性中风研究进展. 李鸿泓,赵辉.《北京中医杂志》,第21卷第1期. 2002 |
益气活血法防治缺血性中风研究进展. 李鸿泓,赵辉.《北京中医杂志》,第21卷第1期. 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1803156A (zh) | 2006-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102847063A (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
CN102698122A (zh) | 用于治疗牙周炎的中药、制备方法、牙膏和给药方式 | |
CN102861287A (zh) | 一种治疗湿热下注淤血型糖尿病足的中药组合物及其制备方法 | |
CN104857288B (zh) | 治疗白发的中药制剂及其制备方法 | |
CN1247231C (zh) | 一种产后补血保健药物及其制备方法和应用 | |
CN103721075B (zh) | 一种用于妇产科术后的中药及其制备方法 | |
CN100388927C (zh) | 一种治疗中风病的药物及制备方法 | |
CN101229345B (zh) | 益气补血药 | |
CN105311492A (zh) | 一种用于冠状动脉粥样硬化性心脏病的药物 | |
CN109528968A (zh) | 一种治疗2型糖尿病的中药组合物及其制备方法和应用 | |
CN105012873A (zh) | 一种降血脂的月见草保健口服液及其制备方法 | |
CN103623361B (zh) | 用于治疗脑血栓的中药组合物 | |
CN109718304A (zh) | 改善人体心脑血管功能微循环及预防血栓的中药组合物 | |
CN109718305A (zh) | 改善人体气血功能提高耐缺氧延缓衰老的中药组合物 | |
CN114272344B (zh) | 一种治疗气阴两虚兼血瘀型脏腑功能失调症的中药组合物、制剂与应用 | |
CN103110783A (zh) | 一种治疗脑萎缩的药物 | |
CN115105587B (zh) | 一种防治心、脑、肺血管疾病的药物组合物 | |
CN107224518A (zh) | 一种可有效治疗ii型糖尿病的汤剂药物及制备方法 | |
CN106581468A (zh) | 一种能够治疗胃溃疡的中药制备方法 | |
CN104258302A (zh) | 一种治疗阴虚火旺型慢性特发性血小板减少性紫癜的中药及制备方法 | |
CN101152247A (zh) | 用于心脑血管疾病的药物组合物及其制备方法 | |
CN105168844A (zh) | 治疗门脉高压症术后血栓形成的药物 | |
CN104173803A (zh) | 一种治疗顽固性鼻衄症的中药制剂 | |
CN106389821A (zh) | 一种治疗输血溶血反应的中药制剂及其制备方法 | |
CN105125886A (zh) | 一种用于预防和治疗糖尿病及其并发症的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000515 Denomination of invention: Medicine for treating apoplexy and its preparing process Granted publication date: 20080521 License type: Exclusive License Open date: 20060719 Record date: 20100909 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000515 Date of cancellation: 20131016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211210 Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi Patentee after: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Address before: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating apoplexy and preparation method thereof Effective date of registration: 20211228 Granted publication date: 20080521 Pledgee: China Construction Bank Corporation Linyi Shizhong sub branch Pledgor: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016801 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230331 Granted publication date: 20080521 Pledgee: China Construction Bank Corporation Linyi Shizhong sub branch Pledgor: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016801 |